Bitte benutzen Sie diese Kennung, um auf die Ressource zu verweisen:
Autoren: Khamis, Aya
Gül, Désirée
Wandrey, Madita
Lu, Qiang
Knauer, Shirley K.
Reinhardt, Christoph
Strieth, Sebastian
Hagemann, Jan
Stauber, Roland H.
Titel: The vitamin D receptor–BIM axis overcomes cisplatin resistance in head and neck cancer
Online-Publikationsdatum: 25-Jan-2023
Erscheinungsdatum: 2022
Sprache des Dokuments: Englisch
Zusammenfassung/Abstract: Treatment success of head and neck squamous cell carcinoma (HNSCC) is often hindered by cisplatin resistance. As inherent and acquired therapy resistance counteracts improvement in long-term survival, novel multi-targeting strategies triggering cancer cell apoptosis are urgently required. Here, we identify the vitamin D receptor (VDR) as being significantly overexpressed in tumors of HNSCC patients (n = 604; p = 0.0059), correlating with tumor differentiation (p = 0.0002), HPV status (p = 0.00026), and perineural invasion (p = 0.0087). The VDR, a member of the nuclear receptor superfamily, is activated by its ligand vitamin D (VitD) and analogs, triggering multiple cellular responses. As we found that the VDR was also upregulated in our cisplatin-resistant HNSCC models, we investigated its effect on overcoming cisplatin resistance. We discovered that VitD/cisplatin combinations synergistically killed even cisplatin-resistant cells at clinically achievable levels. Similar results were obtained for the clinically used VitD analog Maxacalcitol. Moreover, VitD/cisplatin combinations inhibited tumor cell migration by E-cadherin upregulation. Signaling pathway analyses revealed that VitD co-treatments triggered cancer cell death by increasing the expression of the pro-apoptotic BCL-2 family protein BIM. BIM’s pro-apoptotic activity in HNSCC cells was confirmed by ectopic overexpression studies. Importantly, BIM expression is positively associated with HNSCC patients’ (n = 539) prognosis, as high expression correlated with improved survival (p = 0.0111), improved therapy response (p = 0.0026), and remission (p = 0.004). Collectively, by identifying, for the first time, the VDR/BIM axis, we here provide a molecular rationale for the reported anti-cancer activity of VitD/analogs in combination therapies. Our data also suggest its exploitation as a potential strategy to overcome cisplatin resistance in HNSCC and other malignancies by inducing additional pro-apoptotic pathways.
DDC-Sachgruppe: 610 Medizin
610 Medical sciences
Veröffentlichende Institution: Johannes Gutenberg-Universität Mainz
Organisationseinheit: FB 04 Medizin
Veröffentlichungsort: Mainz
Version: Published version
Publikationstyp: Zeitschriftenaufsatz
Weitere Angaben zur Dokumentart: Scientific article
Nutzungsrechte: CC BY
Informationen zu den Nutzungsrechten:
Zeitschrift: Cancers
Seitenzahl oder Artikelnummer: 5131
Verlag: MDPI
Verlagsort: Basel
Erscheinungsdatum: 2022
ISSN: 2072-6694
DOI der Originalveröffentlichung: 10.3390/cancers14205131
Enthalten in den Sammlungen:DFG-491381577-G

Dateien zu dieser Ressource:
  Datei Beschreibung GrößeFormat
the_vitamin_d_receptorbim_axi-20230124115941726.pdf4.57 MBAdobe PDFÖffnen/Anzeigen